Radalbuvir (INN, also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials. It targets NS5B polymerase.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:casNumber |
|
| dbo:fdaUniiCode |
|
| dbo:pubchem |
|
| dbo:thumbnail | |
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink | |
| dbp:c |
|
| dbp:casNumber |
|
| dbp:chemspiderid |
|
| dbp:h |
|
| dbp:iupacName |
|
| dbp:legalUs |
|
| dbp:n |
|
| dbp:o |
|
| dbp:pubchem |
|
| dbp:s |
|
| dbp:smiles |
|
| dbp:stdinchi |
|
| dbp:stdinchikey |
|
| dbp:synonyms |
|
| dbp:unii |
|
| dbp:width |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| gold:hypernym | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:depiction | |
| foaf:isPrimaryTopicOf | |
| isdbo:wikiPageRedirects of | |
| isdbo:wikiPageWikiLink of | |
| isfoaf:primaryTopic of |
